Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heffner

Showing results (931-940 of 1,030) with videos related to

Pageof 103
Sort By:
Journal of Medicinal Chemistry|April 2, 2005
Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta proteinThomas R Belliotti, Thomas Capiris, I Victor Ekhato, et al.
QJM : Monthly Journal of the Association of Physicians|July 15, 2011
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effectsS W Dubrey, D E Reece, V Sanchorawala, et al.
British Journal of Haematology|July 5, 2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phaseDisni Muringampurath-John, David L Jaye, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2023
TMEM161B modulates radial glial scaffolding in neocortical developmentLu Wang, Caleb Heffner, Keng Ioi Vong, et al.
Cell|November 1, 2011
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regenerationEirini Trompouki, Teresa V Bowman, Lee N Lawton, et al.
Nature|September 6, 2023
Thymic mimetic cells function beyond self-toleranceTal Givony, Dena Leshkowitz, Diana Del Castillo, et al.
Pageof 103

Showing results (931-940 of 1,030) with videos related to

Sort By:
Pageof 103
Journal of Medicinal Chemistry|April 2, 2005
Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta proteinThomas R Belliotti, Thomas Capiris, I Victor Ekhato, et al.
QJM : Monthly Journal of the Association of Physicians|July 15, 2011
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effectsS W Dubrey, D E Reece, V Sanchorawala, et al.
British Journal of Haematology|July 5, 2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phaseDisni Muringampurath-John, David L Jaye, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Blood Cancer Discovery|November 15, 2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom MacroglobulinemiaAkhilesh Kaushal, Ajay K Nooka, Allison R Carr, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2023
TMEM161B modulates radial glial scaffolding in neocortical developmentLu Wang, Caleb Heffner, Keng Ioi Vong, et al.
Cell|November 1, 2011
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regenerationEirini Trompouki, Teresa V Bowman, Lee N Lawton, et al.
Nature|September 6, 2023
Thymic mimetic cells function beyond self-toleranceTal Givony, Dena Leshkowitz, Diana Del Castillo, et al.
Pageof 103